Status:
COMPLETED
Hypertriglyceridemia-associated Acute Pancreatitis: Apheresis Vs. Conservative Treatment
Lead Sponsor:
Meir Medical Center
Conditions:
Acute Pancreatitis
Eligibility:
All Genders
18-99 years
Brief Summary
Introduction: Hypertriglyceridemia is one of the etiologies of acute pancreatitis. It may cause severe multi-system disease resulting in high morbidity and mortality. There is controversy regarding th...
Detailed Description
Background: Hypertriglyceridemia causes 1-7% of all acute pancreatitis cases. The mechanism by which excess lipids in the blood cause pancreatitis is not entirely clear. The hypothesis is, that the en...
Eligibility Criteria
Inclusion
- All patients aged 18-99 who were admitted to the intensive care unit in Meir medical hospital between years 2010-2020, whose cause of admission was hypertriglyceridemia-induced acute pancreatitis, defined as abdominal pain, elevated levels of amylase and lipase and blood triglyceride level above 1000 mg/dl, without any other apparent etiology of pancreatitis.
- \-
Exclusion
- None
- \-
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04708925
Start Date
February 1 2021
End Date
October 1 2021
Last Update
April 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meir Medical Center
Kfar Saba, Israel